Your browser doesn't support javascript.
loading
Mapping variant effects on anti-tumor hallmarks of primary human T cells with base-editing screens.
Walsh, Zachary H; Shah, Parin; Kothapalli, Neeharika; Shah, Shivem B; Nikolenyi, Gergo; Brodtman, D Zack; Leuzzi, Giuseppe; Rogava, Meri; Mu, Michael; Ho, Patricia; Abuzaid, Sinan; Vasan, Neil; AlQuraishi, Mohammed; Milner, Joshua D; Ciccia, Alberto; Melms, Johannes C; Izar, Benjamin.
Afiliación
  • Walsh ZH; Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
  • Shah P; Department of Medicine, Division of Hematology and Oncology, Columbia University Irving Medical Center, New York, NY, USA.
  • Kothapalli N; Columbia Center for Translational Immunology, New York, NY, USA.
  • Shah SB; Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, USA.
  • Nikolenyi G; Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
  • Brodtman DZ; Department of Medicine, Division of Hematology and Oncology, Columbia University Irving Medical Center, New York, NY, USA.
  • Leuzzi G; Columbia Center for Translational Immunology, New York, NY, USA.
  • Rogava M; Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, USA.
  • Mu M; Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
  • Ho P; Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
  • Abuzaid S; Department of Systems Biology, Columbia University Irving Medical Center, New York, NY, USA.
  • Vasan N; Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
  • AlQuraishi M; Department of Medicine, Division of Hematology and Oncology, Columbia University Irving Medical Center, New York, NY, USA.
  • Milner JD; Columbia Center for Translational Immunology, New York, NY, USA.
  • Ciccia A; Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, USA.
  • Melms JC; Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, USA.
  • Izar B; Department of Genetics and Development, Columbia University Medical Center, New York, NY, USA.
Nat Biotechnol ; 2024 May 23.
Article en En | MEDLINE | ID: mdl-38783148
ABSTRACT
Single-nucleotide variants (SNVs) in key T cell genes can drive clinical pathologies and could be repurposed to improve cellular cancer immunotherapies. Here, we perform massively parallel base-editing screens to generate thousands of variants at gene loci annotated with known or potential clinical relevance. We discover a broad landscape of putative gain-of-function (GOF) and loss-of-function (LOF) mutations, including in PIK3CD and the gene encoding its regulatory subunit, PIK3R1, LCK, SOS1, AKT1 and RHOA. Base editing of PIK3CD and PIK3R1 variants in T cells with an engineered T cell receptor specific to a melanoma epitope or in different generations of CD19 chimeric antigen receptor (CAR) T cells demonstrates that discovered GOF variants, but not LOF or silent mutation controls, enhanced signaling, cytokine production and lysis of cognate melanoma and leukemia cell models, respectively. Additionally, we show that generations of CD19 CAR T cells engineered with PIK3CD GOF mutations demonstrate enhanced antigen-specific signaling, cytokine production and leukemia cell killing, including when benchmarked against other recent strategies.

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Nat Biotechnol Asunto de la revista: BIOTECNOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Nat Biotechnol Asunto de la revista: BIOTECNOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos